title: Targeting mitochondria by α-tocopheryl succinate overcomes hypoxia-mediated tumor cell resistance to treatment.
abstract: Rapidly proliferating tumor cells easily become hypoxic. This results in acquired stability towards treatment with anticancer drugs. Here, we show that cells grown at 0.1 % oxygen are more resistant towards treatment with the conventionally used anticancer drugs doxorubicin and cisplatin. The stimulation of apoptosis, as assessed by the number of cells in the SubG1 fraction of the cell cycle, release of cytochrome c into the cytosol, activation of caspase-3, and cleavage of PARP, was markedly suppressed under low oxygen content or when hypoxia was mimicked by deferoxamine. Hypoxia or deferoxamine treatment was accompanied by stabilization of the hypoxia-inducible factor (HIF-1). The downregulation of HIF-1 using siRNA technique restored cell sensitivity to treatment under hypoxic conditions to the levels detected under normoxic conditions. In contrast to cisplatin or doxorubicin, α-tocopheryl succinate (α-TOS), a compound that targets mitochondria, stimulated cell death irrespective of the oxygen concentration. Moreover, under hypoxic condition cell death induced by α-TOS was even enhanced. Thus, α-TOS can successfully overcome resistance to treatment caused by hypoxia, which makes α-TOS an attractive candidate for antitumor therapy via mitochondrial targeting.
authors.affiliation: Faculty of Basic Medicine, MV Lomonosov Moscow State University, 119991, Moscow, Russia.
authors.forename: Andrey V
authors.initials: AV
authors.lastname: Kulikov
authors.forename: Alexander S
authors.initials: AS
authors.lastname: Vdovin
authors.forename: Boris
authors.initials: B
authors.lastname: Zhivotovsky
authors.forename: Vladimir
authors.initials: V
authors.lastname: Gogvadze
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D000975:Antioxidants / Q000627:therapeutic use*; D015687:Cell Hypoxia; D002945:Cisplatin / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D045325:HCT116 Cells; D006801:Humans; D008928:Mitochondria / Q000187:drug effects*; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy*; D014407:Tumor Cells, Cultured; D024502:alpha-Tocopherol / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D000975:Antioxidants; D004317:Doxorubicin; D024502:alpha-Tocopherol; D002945:Cisplatin